Pharmacy Medical Policy Updates - Correction
It has been brought to our attention that some of the links were incorrect in the Pharmacy Medical Policy Updates sent on 5/2/22. Below are the corrected links.
Effective June 1, 2022:
- Site of Care Infusion Management
- IL-5 Inhibitors
- Xolair
- Opioids ER
- ATTR Amyloidosis
- ATTR Amyloidosis – Onpattro
- DPP-4 Inhibitors
- Rapid to Intermediate Acting Insulin
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
We apologize for any inconvenience this may has caused. If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.